


A novel Nectin4-targeting CAR-T cell was successfully engineered and validated against bladder cancer

The diabetes drug Rosiglitazone can increase Nectin4 in bladder cancer cells to help these CAR-T cells kill even better!



Novel Nectin4-targeting therapeutic strategies for bladder cancer


Kevin Chang, Jun Zhu, Emily A. Egusa, Alberto C. Gonzalez, Henry Delavan, Carissa E. Chu, Sima P. Porten, Vadim Koshkin, Terence W. Friedlander, Felix Y. Feng, Jonathan Chou



UCSF Department of Urology


BACKGROUND

Surface protein targeting therapies address an urgent need for bladder cancer patients



1. Nectin4-Chimeric Antigen Receptor (CAR)-T cell


Expression of **NECTIN4** was positively correlated with expression of **PPARG**, a key metabolic transcription factor




METHODS

To Date:

- 8 Nectin4-CAR constructs cloned and tested for killing
- 2 candidate CARs validated



RESULTS



CONCLUSIONS & FUTURE DIRECTIONS

- 1) Nectin4-targeting CAR T cells selectively kill bladder cancer cells *in vitro* and *in vivo*
 - clinical-grade CAR T cells, intravesical delivery?
- 2) Rosiglitazone increases Nectin4 expression and sensitivity to a Nectin4-targeting CAR T cell
 - clinical trials using **rational** therapeutic combinations

Therapeutic strategies used in earlier stages of disease to **help patients preserve their bladders!**

Acknowledgements:

Coryn Kasap, Adila Izgutdina from the Wiita Lab
Work was funded by a UCSF Inquiry office yearlong research grant and by the Feng/Chou labs